Actuate Therapeutics (ACTU) vs Bolt Biotherapeutics (BOLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Actuate Therapeutics is the larger company by market cap ($13.6 million vs $12.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | BOLT |
|---|---|---|
| Share price | $0.2253 | $4.91 |
| Market cap | $13.60M | $12.80M |
| 1-day change | +5.38% | -2.96% |
| YTD return | -96.32% | — |
| 1-year return | -96.43% | — |
| EPS (TTM) | $-0.76 | $-14.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $7.70M |
| Revenue growth (YoY) | — | +0.07% |
| Net income (latest FY) | $-22.23M | $-33.38M |
| Operating margin | — | -469.30% |
| Net margin | — | -433.74% |
| 52-week high | $7.90 | $7.78 |
| 52-week low | $0.174 | $3.10 |
| Distance from 52-week high | -97.15% | -36.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +5084.20% | +490.63% |
| Average volume | 807.24K | 257.43K |
| Shares outstanding | 60.38M | 2.61M |
| Employees | 12 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ACTU vs BOLT FAQ
Which is bigger, Actuate Therapeutics or Bolt Biotherapeutics?
Actuate Therapeutics (ACTU) is larger, with a market capitalization of $13.60M compared with $12.80M for Bolt Biotherapeutics (BOLT).
Are Actuate Therapeutics and Bolt Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.